• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

局部进展期肝细胞癌新辅助多模态治疗的影响。

Impact of neoadjuvant multimodal therapy in the setting of locally advanced hepatocellular carcinoma.

机构信息

Hepato-biliary and Liver Transplant Centre, Department of General Surgery and Woman's Health, AORN Antonio Cardarelli, Naples 80131, Italy.

出版信息

World J Gastroenterol. 2024 Jul 28;30(28):3452-3455. doi: 10.3748/wjg.v30.i28.3452.

DOI:10.3748/wjg.v30.i28.3452
PMID:39091715
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11290390/
Abstract

Immunotherapy and the implementation of more aggressive treatment schemes for locally advanced hepatocellular carcinomas have expanded the boundaries of curative options. Because of these advancements, patients who were once considered beyond the aim of a cure are now eligible for liver transplantation and resection.

摘要

免疫疗法和更积极的局部晚期肝细胞癌治疗方案的实施扩大了治疗选择的范围。由于这些进展，曾经被认为无法治愈的患者现在有资格接受肝移植和切除术。

相似文献

1
Impact of neoadjuvant multimodal therapy in the setting of locally advanced hepatocellular carcinoma.局部进展期肝细胞癌新辅助多模态治疗的影响。
World J Gastroenterol. 2024 Jul 28;30(28):3452-3455. doi: 10.3748/wjg.v30.i28.3452.
2
Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma.肝细胞癌的新辅助和辅助治疗策略。
World J Gastroenterol. 2019 Jul 28;25(28):3704-3721. doi: 10.3748/wjg.v25.i28.3704.
3
Radioembolization for Hepatocellular Carcinoma in Downstaging and Bridging for Liver Transplantation.放射性栓塞治疗肝癌以降期和桥接进行肝移植。
J Gastrointest Cancer. 2020 Dec;51(4):1157-1164. doi: 10.1007/s12029-020-00492-y.
4
Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma.早期和中期肝细胞癌新型全身治疗的现状和未来。
World J Gastroenterol. 2024 May 21;30(19):2512-2522. doi: 10.3748/wjg.v30.i19.2512.
5
Conversion therapy and maintenance therapy for primary hepatocellular carcinoma.原发性肝癌的转化治疗和维持治疗。
Biosci Trends. 2021 Jul 6;15(3):155-160. doi: 10.5582/bst.2021.01091. Epub 2021 May 27.
6
Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria.对于超出米兰标准的肝细胞癌，先进行降期治疗，然后进行肝移植。
Surgery. 2017 Dec;162(6):1250-1258. doi: 10.1016/j.surg.2017.08.007. Epub 2017 Oct 13.
7
Immunotherapy as a Downstaging Tool for Liver Transplantation in Hepatocellular Carcinoma.免疫疗法作为肝细胞癌肝移植的降期工具
Am J Gastroenterol. 2021 Dec 1;116(12):2478-2480. doi: 10.14309/ajg.0000000000001391.
8
Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: where do we stand?肝移植前肝细胞癌的新辅助治疗：我们目前的进展如何？
World J Gastroenterol. 2014 May 14;20(18):5308-19. doi: 10.3748/wjg.v20.i18.5308.
9
Treatment of hepatocellular carcinoma.肝细胞癌的治疗。
Oncology. 2009;77 Suppl 1:43-9. doi: 10.1159/000258495. Epub 2010 Feb 2.
10
Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal.肝移植前肝细胞癌的新辅助治疗：批判性评估
Liver Transpl. 2006 Dec;12(12):1747-54. doi: 10.1002/lt.21018.

本文引用的文献

1
Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus.经导管动脉化疗栓塞联合 PD-1 抑制剂和仑伐替尼治疗伴有门静脉癌栓的肝细胞癌。
World J Gastroenterol. 2024 Feb 28;30(8):843-854. doi: 10.3748/wjg.v30.i8.843.
2
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma.辅助和新辅助免疫疗法在肝细胞癌中的应用。
Nat Rev Clin Oncol. 2024 Apr;21(4):294-311. doi: 10.1038/s41571-024-00868-0. Epub 2024 Feb 29.
3
Watch-and-wait strategy vs. resection in patients with radiologic complete response after conversion therapy for initially unresectable hepatocellular carcinoma: a propensity score-matching comparative study.影像学完全缓解后转换治疗初不可切除的肝细胞癌患者的观察等待策略与切除术比较：倾向评分匹配的对比研究。
Int J Surg. 2024 May 1;110(5):2545-2555. doi: 10.1097/JS9.0000000000001155.
4
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.特瑞利木单抗联合度伐利尤单抗治疗不可切除肝细胞癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6.
5
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.阿替利珠单抗联合贝伐珠单抗对比主动监测用于治疗接受手术切除或消融治疗的高风险肝细胞癌患者（IMbrave050）：一项随机、开放标签、多中心、III 期临床试验。
Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20.
6
Systemic therapy with lenvatinib in advanced hepatocellular carcinoma: what to do in the case of a complete radiologic response?乐伐替尼用于晚期肝细胞癌的全身治疗：出现完全影像学缓解时该怎么做？
J Gastrointestin Liver Dis. 2023 Apr 1;32(1):118-119. doi: 10.15403/jgld-4811.
7
Deceased Donor Liver Transplantation After Radioembolization for Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: A Pilot Study.经动脉化疗栓塞术治疗肝细胞癌合并门静脉癌栓后行肝移植治疗：一项试点研究。
Liver Transpl. 2021 Dec;27(12):1758-1766. doi: 10.1002/lt.26257. Epub 2021 Sep 8.
8
Locoregional Therapy Protocols With and Without Radioembolization for Hepatocellular Carcinoma as Bridge to Liver Transplantation.局部区域治疗方案联合或不联合放射性栓塞用于肝癌桥接肝移植。
Am J Clin Oncol. 2020 May;43(5):325-333. doi: 10.1097/COC.0000000000000678.
9
Experience With LDLT in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis Postdownstaging.肝癌伴门静脉癌栓患者降期后 LDLT 的经验。
Transplantation. 2020 Nov;104(11):2334-2345. doi: 10.1097/TP.0000000000003162.
10
Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion - a multi-center retrospective cohort study.肝癌伴大血管侵犯经治疗后行肝移植的多中心回顾性队列研究。
Transpl Int. 2020 May;33(5):567-575. doi: 10.1111/tri.13586. Epub 2020 Feb 20.